Comparative proteomic analysis implicates eEF2 as a novel target of PI3Kγ in the MDA-MB-231 metastatic breast cancer

Meizhi Niu1, Manuela Klingler-Hoffmann1, Julie A Brazzatti1,2

  • 1School of Molecular and Biomedical Science, University of Adelaide, Adelaide, SA 5005, Australia.

Proteome Science
|January 17, 2013
PubMed
Abstract

Insights

This study identifies a new pathway in breast cancer cell migration. Phosphoinositide 3-kinase gamma (PI3Kγ) regulates eukaryotic elongation factor 2 (eEF2) phosphorylation, impacting cancer cell movement.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Signaling

Background:

  • Breast cancer metastasis involves cell migration, with insulin-like growth factor 1 tyrosine kinase receptor (IGF-1R) and CXCR4 playing key roles.
  • Previous research demonstrated IGF-1R transactivates CXCR4, driving migration in MDA-MB-231 cells.

Purpose of the Study:

  • To identify signaling molecules downstream of IGF-1R/CXCR4 transactivation.
  • To investigate the role of phosphoinositide 3-kinase gamma (PI3Kγ) in IGF-I-induced breast cancer cell migration.
  • To identify proteins regulated by PI3Kγ following receptor transactivation.

Main Methods:

  • Pharmacological inhibition and RNA interference (RNAi) were used to study PI3Kγ.
  • Comparative proteomics, including 2-D-Fluorescence Difference Gel Electrophoresis (DIGE), was employed.
  • Mass spectrometry was used for protein identification.

Main Results:

  • Eukaryotic elongation factor 2 (eEF2) was identified as a novel downstream target of PI3Kγ.
  • IGF-I stimulation of the IGF-1R-CXCR4 heterodimer led to eEF2 phosphorylation.
  • eEF2 phosphorylation was dependent on PI3Kγ activity in MDA-MB-231 cells.

Conclusions:

  • PI3Kγ plays a novel role in regulating eEF2 phosphorylation.
  • This regulation by PI3Kγ contributes to facilitating cancer cell migration.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...